Drugmaker Files Emergency Appeal After Court Limits Mifepristone Access

Court Restricts Nationwide Access

A federal appeals court on Friday rolled back access to the abortion pill mifepristone nationwide. The decision by the 5th US Circuit Court of Appeals reinstated a nationwide requirement that the medication be obtained in person. This ruling effectively blocks the distribution of the drug via mail or through pharmacies using telemedicine.

Circuit Judge Stuart Kyle Duncan wrote in the panel's opinion that the district court had previously agreed Louisiana was likely to win its challenge to the mifepristone regulation and was suffering irreparable harm. While the district court had declined to stay the regulation based on public interest and equities, the 5th Circuit granted the stay.

Emergency Legal Response

In response to the ruling, drugmaker Danco Laboratories filed an emergency motion requesting a one-week pause through May 8. This pause is intended to allow the company to seek an opinion from the Supreme Court. Danco requested a decision on this motion from the circuit court by 9 p.m. Central time, stating that the ruling has resulted in "immediate chaos".

In its filing, Danco argued that the legal status of the drug's distribution is currently ambiguous, stating, "It is now unclear whether pharmacies nationwide may still dispense mifepristone to women tonight". The company further noted that it is unclear what providers and patients should do regarding appointments scheduled for the coming weekend or early next week.

Impact on Healthcare and Patients

Mifepristone is used in nearly two-thirds of all pregnancy terminations in the United States. Approximately one-quarter of patients who use the medication rely on telehealth to obtain it. The court's decision to reinstate in-person requirements specifically curbs access in states where abortion is banned.

Beyond abortion, the ruling also cuts off the use of telemedicine prescriptions for non-abortion purposes, including the management of miscarriages. Medical and progressive advocacy groups have noted that doctors can still use telehealth to prescribe misoprostol, another abortion pill that can be used independently to end pregnancies and is subject to fewer restrictions.

Regina Davis Moss, CEO of the advocacy group In Our Own Voice, stated that restricting access to the medication is "unconscionable" at a time when families struggle with costs for housing, groceries, and child care. Moss added that reinstating in-person dispensing requirements would force patients to absorb higher costs and take more time off work to travel farther.

Legal Context and Next Steps

This emergency appeal, filed with conservative Justice Samuel Alito, returns the issue of mifepristone to the Supreme Court's docket. This occurs less than two years after the high court rejected a similar challenge, a decision that had allowed the drug to remain widely available. In that 2024 case, the Supreme Court threw out the challenge after finding that the doctors who brought the case lacked legal standing.

Evan Masingill, CEO of GenBioPro, a pharmaceutical company that manufactures a generic version of mifepristone, stated that his company remains committed to making the medication available and accessible.